Albiglutide

Albiglutide, marketed by GSK as Tanzeum, was a once-weekly GLP-1 receptor agonist for type 2 diabetes. It is included in this glossary not because you might be prescribed it — you cannot be — but because its story explains something patients keep running into.

GSK withdrew the drug from global markets in 2017, citing limited commercial uptake rather than a safety problem. The following year, The Lancet published HARMONY OUTCOMES, the cardiovascular trial that had already been running. It enrolled 9,463 adults with type 2 diabetes and established cardiovascular disease and reported the primary composite in 7% on albiglutide versus 9% on placebo — a hazard ratio of 0.78, superior to placebo, over a median of only 1.6 years.

So a drug that had been discontinued for business reasons turned out to deliver one of the cleaner cardiovascular results in its class. Nothing about the withdrawal was a safety judgment, and nothing about the trial brought the drug back.

The lesson is a practical filter for reading drug news. A published trial result and an available prescription are two different things, and a drug’s presence on the market reflects commercial decisions at least as much as evidence. AMPLITUDE-O and efpeglenatide repeated the pattern in 2021, and investigational agents such as pemvidutide and mazdutide may or may not clear the same commercial hurdles regardless of how their trials read.

Worth asking your clinician: which GLP-1 agents are currently available and covered by your plan, and whether a drug you read about is approved in the United States at all. Our HARMONY OUTCOMES deep dive, pipeline tracker and cardiovascular study roundup keep the distinction straight.